Literature DB >> 22174446

Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.

Shari N Gordon1, Rhonda C Kines, Galyna Kutsyna, Zhong-Min Ma, Anna Hryniewicz, Jeffery N Roberts, Claudio Fenizia, Rachmat Hidajat, Egidio Brocca-Cofano, Nicolas Cuburu, Christopher B Buck, Marcelino L Bernardo, Marjorie Robert-Guroff, Christopher J Miller, Barney S Graham, Douglas R Lowy, John T Schiller, Genoveffa Franchini.   

Abstract

The majority of HIV infections occur via mucosal transmission. Vaccines that induce memory T and B cells in the female genital tract may prevent the establishment and systemic dissemination of HIV. We tested the immunogenicity of a vaccine that uses human papillomavirus (HPV)-based gene transfer vectors, also called pseudovirions (PsVs), to deliver SIV genes to the vaginal epithelium. Our findings demonstrate that this vaccine platform induces gene expression in the genital tract in both cynomolgus and rhesus macaques. Intravaginal vaccination with HPV16, HPV45, and HPV58 PsVs delivering SIV Gag DNA induced Gag-specific Abs in serum and the vaginal tract, and T cell responses in blood, vaginal mucosa, and draining lymph nodes that rapidly expanded following intravaginal exposure to SIV(mac251.) HPV PsV-based vehicles are immunogenic, which warrant further testing as vaccine candidates for HIV and may provide a useful model to evaluate the benefits and risks of inducing high levels of SIV-specific immune responses at mucosal sites prior to SIV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22174446      PMCID: PMC3253208          DOI: 10.4049/jimmunol.1101404

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Predominate HIV1-specific IgG activity in various mucosal compartments of HIV1-infected individuals.

Authors:  F X Lü
Journal:  Clin Immunol       Date:  2000-10       Impact factor: 3.969

2.  Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Peng Xiao; Jun Zhao; L Jean Patterson; Egidio Brocca-Cofano; David Venzon; Pamela A Kozlowski; Rachmat Hidajat; Thorsten Demberg; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

3.  Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.

Authors:  Jeffrey N Roberts; Rhonda C Kines; Hormuzd A Katki; Douglas R Lowy; John T Schiller
Journal:  J Natl Cancer Inst       Date:  2011-04-11       Impact factor: 13.506

4.  Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys.

Authors:  Jinyan Liu; Brandon F Keele; Hui Li; Sheila Keating; Philip J Norris; Angela Carville; Keith G Mansfield; Georgia D Tomaras; Barton F Haynes; Dror Kolodkin-Gal; Norman L Letvin; Beatrice H Hahn; George M Shaw; Dan H Barouch
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

6.  A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251.

Authors:  Mars Stone; Brandon F Keele; Zhong-Min Ma; Elizabeth Bailes; Joseph Dutra; Beatrice H Hahn; George M Shaw; Christopher J Miller
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

7.  Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro.

Authors:  M P Rudolf; S C Fausch; D M Da Silva; W M Kast
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

8.  Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.

Authors:  B S Graham; R C Kines; K S Corbett; J Nicewonger; T R Johnson; M Chen; D LaVigne; J N Roberts; N Cuburu; J T Schiller; C B Buck
Journal:  Mucosal Immunol       Date:  2010-06-16       Impact factor: 7.313

9.  Efficient intracellular assembly of papillomaviral vectors.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.

Authors:  Scott G Hansen; Julia C Ford; Matthew S Lewis; Abigail B Ventura; Colette M Hughes; Lia Coyne-Johnson; Nathan Whizin; Kelli Oswald; Rebecca Shoemaker; Tonya Swanson; Alfred W Legasse; Maria J Chiuchiolo; Christopher L Parks; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Michael Piatak; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2011-05-11       Impact factor: 49.962

View more
  15 in total

1.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

Review 2.  Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

3.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

4.  Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.

Authors:  Nicolas Çuburu; Barney S Graham; Christopher B Buck; Rhonda C Kines; Yuk-Ying S Pang; Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

5.  Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Authors:  Nicolas Çuburu; Kening Wang; Kyle N Goodman; Yuk Ying Pang; Cynthia D Thompson; Douglas R Lowy; Jeffrey I Cohen; John T Schiller
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 6.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

Review 7.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

8.  Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene.

Authors:  Chien-Fu Hung; An Jen Chiang; Hsiao-Hsuan Tsai; Martin G Pomper; Tae Heung Kang; Richard R Roden; T-C Wu
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

9.  Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.

Authors:  Rhonda C Kines; Vladimir Zarnitsyn; Teresa R Johnson; Yuk-Ying S Pang; Kizzmekia S Corbett; John D Nicewonger; Anu Gangopadhyay; Man Chen; Jie Liu; Mark R Prausnitz; John T Schiller; Barney S Graham
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 10.  Challenges in mucosal HIV vaccine development: lessons from non-human primate models.

Authors:  Iskra Tuero; Marjorie Robert-Guroff
Journal:  Viruses       Date:  2014-08-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.